Featured Press Releases

Eisai strengthens its presence in Saudi Arabia by establishing a new pharmaceutical sales subsidiary to enhance its operations in the region

Eisai strengthens its presence in Saudi Arabia by establishing a new pharmaceutical sales subsidiary to enhance its operations in the region

Corundum Systems Biology appoints Jessica Schneider as Chief Scientific Officer

Corundum Systems Biology appoints Jessica Schneider as Chief Scientific Officer

  • 04 Sep 2024

Corundum Systems Biology, a leading investment company  dedicated to advancing life-changing...

Cardurion Pharmaceuticals has named Charlotte Newman as Chief Business Officer

Cardurion Pharmaceuticals has named Charlotte Newman as Chief Business Officer

Doer Biologics announces the dosing of the first patient in a Phase 2 study of DR10624 for severe hypertriglyceridemia treatment.

Doer Biologics announces the dosing of the first patient in a Phase 2 study of DR10624 for severe hypertriglyceridemia treatment.

Ark Biopharmaceutical Granted China Marketing Authorization for Aizhida in ADHD Treatment

Ark Biopharmaceutical Granted China Marketing Authorization for Aizhida in ADHD Treatment

Clover Begins Phase 2 Clinical Evaluation of a Combination Respiratory Vaccine Targeting RSV, hMPV, and ± PIV3

Clover Begins Phase 2 Clinical Evaluation of a Combination Respiratory Vaccine Targeting RSV, hMPV, and ± PIV3

FDA Grants KORU Medical Systems 510(k) Clearance for RYSTIGGO® Delivery via FreedomEDGE® Infusion System

FDA Grants KORU Medical Systems 510(k) Clearance for RYSTIGGO® Delivery via FreedomEDGE® Infusion System

  • KORU Medical Systems, Inc.
  • 02 Feb 2026
Tonix Pharmaceuticals presented Phase 3 RESILIENT data on TONMYA™ (cyclobenzaprine HCl sublingual tablets) at the 2026 Non-Opioid Pain Therapeutics Summit

Tonix Pharmaceuticals presented Phase 3 RESILIENT data on TONMYA™ (cyclobenzaprine HCl sublingual tablets) at the 2026 Non-Opioid Pain Therapeutics Summit

  • Tonix Pharmaceuticals Holding Corp.
  • 30 Jan 2026
China approves Libevitug, first-in-class therapy for hepatitis D

China approves Libevitug, first-in-class therapy for hepatitis D

  • Huahui Health Ltd.
  • 28 Jan 2026
DARZALEX FASPRO® quadruplet approved in U.S. for transplant-ineligible multiple myeloma patients

DARZALEX FASPRO® quadruplet approved in U.S. for transplant-ineligible multiple myeloma patients

  • Johnson & Johnson
  • 27 Jan 2026
Correction — Privo Technologies

Correction — Privo Technologies

  • Privo Technologies
  • 26 Jan 2026
HanchorBio Partners with WuXi Biologics to Advance Next-Generation Fusion Protein Pipeline

HanchorBio Partners with WuXi Biologics to Advance Next-Generation Fusion Protein Pipeline

  • HanchorBio Inc.
  • 26 Jan 2026
World Drug Delivery Summit 2025
The Digital Pharma Advances Conference 2026

Most Popular
February   2026
M T W T F S S
            1
2 3 4 5 6 7 8
9 10 11 12 13 14 15
16 17 18 19 20 21 22
23 24 25 26 27 28  

User Area

Discover

Engage with Us

© Pharmaceutical Era — A product of HISSM. All Rights Reserved.